Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy

A method of treating a patient suffering from gout having a serum uric acid (SUA) level of 6 mg/dl or less, and reducing the incidence of infusion reaction in said patient, the method comprising:

• administering to said patient, a PEGylated uricase at a dosage of 8 mg every two weeks;
• after a first period of time, determining the SUA level of said patient, and
• if said SUA level of the patient is maintained below 6 mg/dl, continuing said administration of PEGylated uricase at a dosage of 8 mg every two weeks, whereas if said SUA level of the patient is above 6 mg/dl, discontinuing said administration thereby reducing the incidence of infusion reaction in said patient, wherein said patient previously received ineffective allopurinol therapy or has a medical history in which allopurinol therapy is contraindicated.